ライフサイエンスコーパス: hepatitis C virus

1 is of human immunodeficiency virus (HIV) and hepatitis C virus .

2 rapy, and, if applicable, elimination of the hepatitis C virus.

3 d protein are associated with changes in the hepatitis C virus.

4 er of patients undergoing reLT for recurrent hepatitis C virus.

5 logies were nonalcoholic steatohepatitis and hepatitis C virus.

6 proteins of human immunodeficiency virus and hepatitis C virus.

7 less than that of human immunodeficiency and hepatitis C viruses.

8 ridae family, including Zika, West Nile, and hepatitis C viruses.

9 due to hepatitis B virus (12.2 million) and hepatitis C virus (10.4 million), liver cancer due to he

10 After the discovery of hepatitis C virus 3 decades ago, the identification of t

11 SIV), irrespective of virus tropism, but not hepatitis C virus, adenovirus 5 (ADV5), Zika virus, and

12 The WHO elimination strategy for hepatitis C virus advocates scaling up screening and tre

13 f the mechanisms by which hepatitis B virus, hepatitis C virus, alcohol, fatty liver disease, and oth

14 f hepatitis C viral inhibitors and comparing hepatitis C virus and coronavirus replication, we previo

15 irment (stage 4 chronic kidney disease), and hepatitis C virus and hepatitis B virus infections.

16 targets of interest (Plasmodium falciparum, Hepatitis C virus and T-cells) to demonstrate the value

17 coronavirus, human immunodeficiency virus 1, hepatitis C virus, and Japanese encephalitis virus.

18 core antibody (anti-HBc), antibodies against hepatitis C virus (anti-HCV).

19 e 1, Human Immunodeficiency Virus type 1 and Hepatitis C Virus as well as in the inflammatory conditi

20 ses, decompensated cirrhosis, cirrhosis, and hepatitis C virus compared to patients with chronic HBV.

21 re, we address this question by studying the hepatitis C virus core protein, a chaperone that promote

22 Hepatitis C virus cure in coinfection brings monocyte ac

23 The glycoproteins of hepatitis C virus, E1E2, are unlike any other viral fusi

24 e initially insoluble N-terminal fragment of hepatitis C virus' E2 protein were tested.

25 ection with tuberculosis and HIV and HIV and hepatitis C virus exist.

26 nstable housing, previous incarceration, and hepatitis C virus exposure.

27 merase that catalyzes the replication of the hepatitis C virus genome.

28 id agonist therapy (OAT) reduces the risk of hepatitis C virus (HCV) acquisition among people who inj

29 Hepatitis C virus (HCV) among people living in detention

30 Microelimination of hepatitis C virus (HCV) among people living with human i

31 Patients with hepatitis C virus (HCV) and advanced fibrosis remain at

32 Hepatitis C virus (HCV) and alcohol use are patient risk

33 obtained from unrelated cases infected with hepatitis C virus (HCV) and compared its performance wit

34 Hepatitis C virus (HCV) and hepatic dysfunction are asso

35 Hepatitis C virus (HCV) and hepatitis B virus (HBV) infe

36 eath and tumoral recurrence in patients with hepatitis C virus (HCV) and hepatocellular carcinoma (HC

37 Patients were tested for HBV, hepatitis C virus (HCV) and HIV.

38 cure for patients chronically infected with hepatitis C virus (HCV) and improved post-liver transpla

39 ) can be used to circumvent these issues for hepatitis C virus (HCV) and norovirus.

40 e who inject drugs have a high prevalence of hepatitis C virus (HCV) and significant disease associat

41 Hepatitis C virus (HCV) and the opioid epidemic dispropo

42 pendency is a hallmark of the human pathogen hepatitis C virus (HCV) and was also described for the r

43 Hepatitis C virus (HCV) antigen testing is less expensiv

44 We investigated antibody responses to hepatitis C virus (HCV) antigens E1 and E2 and the relev

45 ation step in the synthesis of simeprevir, a hepatitis C virus (HCV) antiviral drug, was studied.

46 Immune-competent animal models for the hepatitis C virus (HCV) are nonexistent, impeding studie

47 WHO aims to eliminate the hepatitis C virus (HCV) as a public health threat by 203

48 Hepatitis C virus (HCV) as indication for LT decreased s

49 Hepatitis C virus (HCV) as indication for LT decreased s

50 who inject drugs (PWID) have had the highest hepatitis C virus (HCV) burden; however, young PWID now

51 care and treatment for persons infected with hepatitis C virus (HCV) can reduce HCV-related morbidity

52 We constructed a hepatitis C virus (HCV) care cascade for adults in Georg

53 Hepatitis B virus (HBV) and hepatitis C virus (HCV) cause 1.3 million deaths annuall

54 For example, hepatitis C virus (HCV) causes a specific, large-fold in

55 Hepatitis C virus (HCV) causes acute hepatitis C and can

56 Here, we show that hepatitis C virus (HCV) co-opts the host protein CypA to

57 years was 49.3 among hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfected and 18.2 among HCV mo

58 mation in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection increases cognitive

59 -associated substitutions (RAS) could hamper hepatitis C virus (HCV) cure rates and elimination effor

60 Global control of hepatitis C virus (HCV) depends on development of a prop

61 (OAT) and compared once-daily to twice-daily hepatitis C virus (HCV) direct-acting antiviral (DAA) th

62 Hepatitis C virus (HCV) direct-acting antivirals are hig

63 Hepatitis C virus (HCV) disproportionately affects disad

64 the long-term outcomes in hepatitis B (HBV)/hepatitis C virus (HCV) dual-infected patients after ant

65 ose, human immunodeficiency virus (HIV), and hepatitis C virus (HCV) due to injection drug use (IDU)

66 iological function for the p7 viroporin from hepatitis C virus (HCV) during virus entry, but also ena

67 The World Health Organization's (WHO) hepatitis C virus (HCV) elimination target of an 80% red

68 To achieve the World Health Organization hepatitis C virus (HCV) elimination targets, it is essen

69 tant component of the response to the global hepatitis C virus (HCV) epidemic.

70 The objective was to delineate hepatitis C virus (HCV) epidemiology in countries of Cen

71 arcinoma (HCC) risk declines over time after hepatitis C virus (HCV) eradication.

72 Most U.S. children with perinatal hepatitis C virus (HCV) exposure fail to receive the rec

73 The mechanism by which hepatitis C virus (HCV) gains entry into cells is a comp

74 Hepatitis C virus (HCV) genotype (gt) 3 is highly preval

75 y and safety in a phase IIa study in chronic hepatitis C virus (HCV) genotype (GT)-1-infected patient

76 th pibrentasvir is approved to treat chronic hepatitis C virus (HCV) genotype 1-6 infection in adults

77 Hepatitis C virus (HCV) genotype 4 is highly heterogeneo

78 s in the treatment of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, 4, or 6.

79 of-life (HRQL) improvements in patients with hepatitis C virus (HCV) has been generally accepted.

80 Mortality associated with hepatitis C virus (HCV) has been well-documented nationa

81 k of immunocompetent small animal models for hepatitis C virus (HCV) has greatly hindered the develop

82 e and safe direct-acting antivirals to treat hepatitis C virus (HCV) has resulted in greater ease and

83 y effective direct-acting antivirals against Hepatitis C virus (HCV) have created an opportunity to t

84 Direct-acting antivirals (DAAs) targeting hepatitis C virus (HCV) have revolutionized outcomes in

85 Limited treatment data are available for hepatitis C virus (HCV) in sub-Saharan Africa, especiall

86 cting antiviral therapy is expected to abate hepatitis C virus (HCV) incidence among human immunodefi

87 Hepatitis C virus (HCV) incidence has increased in the w

88 Micro-elimination of the hepatitis C virus (HCV) includes treatment in population

89 Hepatitis C virus (HCV) infection among maintenance hemo

90 g for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection among persons who inje

91 requent complication associated with chronic hepatitis C virus (HCV) infection and is a key prognosti

92 Kidneys from donors with hepatitis C virus (HCV) infection are traditionally cons

93 lth Organization has set a goal to eliminate hepatitis C virus (HCV) infection as public health threa

94 al natural killer (NK) cell responses during hepatitis C virus (HCV) infection can be restored after

95 Chronic hepatitis C virus (HCV) infection causes decreased expre

96 of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection for patients with a hi

97 Since 2002, a global epidemic of acute hepatitis C virus (HCV) infection has been noted in men

98 t of direct-acting antiviral agents to treat hepatitis C virus (HCV) infection has raised the possibi

99 Although adaptive immune responses against hepatitis C virus (HCV) infection have been studied in g

100 Chronic hepatitis C virus (HCV) infection in Asia is characteriz

101 ion, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney dise

102 Treatment uptake for hepatitis C virus (HCV) infection in people who inject d

103 Most persons with chronic hepatitis C virus (HCV) infection in the United States a

104 though curative therapy is now available for hepatitis C virus (HCV) infection in the United States,

105 resulted in an increase in organ donors with hepatitis C virus (HCV) infection in the United States.

106 an safely prevent the development of chronic hepatitis C virus (HCV) infection in uninfected recipien

107 liver-related mortality among patients with hepatitis C virus (HCV) infection increased from 2007 th

108 Liver disease as a result of chronic hepatitis C virus (HCV) infection is a global problem.

109 Hepatitis C virus (HCV) infection is a global public hea

110 Chronic hepatitis C virus (HCV) infection is a leading cause of

111 Hepatitis C virus (HCV) infection is a major cause of ch

112 BACKGROUNDChronic hepatitis C virus (HCV) infection is characterized by a

113 Chronic hepatitis C virus (HCV) infection is characterized by ac

114 Chronic hepatitis C virus (HCV) infection is characterized by pe

115 Hepatitis C virus (HCV) infection is common among people

116 Hepatitis C virus (HCV) infection is highly prevalent am

117 Chronic hepatitis C virus (HCV) infection is one of the major ca

118 Hepatitis C virus (HCV) infection is the main cause of h

119 Untreated, chronic hepatitis C virus (HCV) infection may lead to progressiv

120 A comprehensive strategy to control hepatitis C virus (HCV) infection needs a vaccine.

121 croglobulin and CD40 antigen and presence of hepatitis C virus (HCV) infection predicted early (year

122 Hepatitis C virus (HCV) infection promotes hepatocyte gr

123 in nuclear morphology of liver cells due to hepatitis C virus (HCV) infection using this model.

124 Risk factors for hepatitis C virus (HCV) infection vary, and there were a

125 erum aspartate aminotransferase (AST) value, Hepatitis C virus (HCV) infection, alcohol abuse, CD4/CD

126 abase was used to identify adults with NASH, hepatitis C virus (HCV) infection, and alcohol-related l

127 important role in immune-mediated control of hepatitis C virus (HCV) infection, but the relative cont

128 inject drugs (PWID) are denied treatment for hepatitis C virus (HCV) infection, even if they are rece

129 ldren under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently n

130 In hepatitis C virus (HCV) infection, virus-specific CD8+ T

131 Despite recent breakthroughs in treatment of hepatitis C virus (HCV) infection, we have limited under

132 s associated with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, with or without a sus

133 Africa has a large population of people with hepatitis C virus (HCV) infection, yet little is known a

134 Chronic hepatitis C virus (HCV) infection-associated liver disea

135 million people are chronically infected with hepatitis C virus (HCV) infection.

136 sing outcomes using kidneys from donors with hepatitis C virus (HCV) infection.

137 transmission is the major cause of pediatric hepatitis C virus (HCV) infection.

138 apies has led to consider the elimination of hepatitis C virus (HCV) infection.

139 llion people worldwide are estimated to have hepatitis C virus (HCV) infection.

140 gimens are safe and effective at eradicating hepatitis C virus (HCV) infection.

141 treatment regimens for patients with chronic hepatitis C virus (HCV) infection.

142 CD4+ T cell failure is a hallmark of chronic hepatitis C virus (HCV) infection.

143 direct-acting antiviral treatment (DAA) for hepatitis C virus (HCV) infection.

144 Sexually transmitted acute hepatitis C virus (HCV) infections (AHIs) have been main

145 Sexually acquired hepatitis C virus (HCV) infections among human immunodef

146 Increasing numbers of hepatitis C virus (HCV) infections among men who have se

147 Current guidelines for the management of hepatitis C virus (HCV) infections provide varying recom

148 FDA-approved drug used for the treatment of hepatitis C virus (HCV) infections, is a potent antivira

149 elaprevir-an FDA-approved drug used to treat hepatitis C virus (HCV) infections-as a potent antiviral

150 services, has contributed to a sharp rise in hepatitis C virus (HCV) infections.

151 ations and scale-up scenarios of combination hepatitis C virus (HCV) interventions for exhaustive tes

152 The hepatitis C virus (HCV) IRES binds eukaryotic translatio

153 Hepatitis C virus (HCV) is a blood borne pathogen mostly

154 Hepatitis C virus (HCV) is a highly variable pathogen th

155 Advanced liver disease due to hepatitis C virus (HCV) is a leading cause of human immu

156 tions for HCV vaccine development.IMPORTANCE Hepatitis C virus (HCV) is a leading cause of liver-rela

157 e assembly.IMPORTANCE Chronic infection with hepatitis C virus (HCV) is a major cause of severe liver

158 An effective vaccine for hepatitis C virus (HCV) is a major unmet need, and it re

159 Hepatitis C virus (HCV) is a positive-sense RNA virus th

160 Hepatitis C virus (HCV) is common among people living wi

161 The quantification of hepatitis C virus (HCV) is essential for the management

162 Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) is highly effective.

163 Hepatitis C virus (HCV) is highly efficient in establish

164 o drive ongoing viral replication.IMPORTANCE Hepatitis C virus (HCV) is known for its ability to modu

165 The E2 glycoprotein of hepatitis C virus (HCV) is the major target of broadly n

166 Hepatitis C virus (HCV) is the most common bloodborne pa

167 Hepatitis C virus (HCV) is the most common chronic blood

168 Sexual transmission of hepatitis C virus (HCV) is uncommon, yet documented amon

169 A vaccine for hepatitis C virus (HCV) is urgently needed.

170 REV-ERBalpha influence several steps in the hepatitis C virus (HCV) life cycle, including particle e

171 rals (DAAs) has transformed the landscape of hepatitis C virus (HCV) management.

172 Hepatitis C virus (HCV) may increase pulmonary hypertens

173 Hepatitis C virus (HCV) nonstructural protein 2 (NS2) is

174 The hepatitis C virus (HCV) nonstructural protein 5A (NS5A)

175 The hepatitis C virus (HCV) NS3-NS4A protease complex is req

176 The discovery of a pan-genotypic hepatitis C virus (HCV) NS3/4A protease inhibitor based

177 mapping of the specificity landscape of the hepatitis C virus (HCV) NS3/4A protease, whose function-

178 Hepatitis C virus (HCV) nucleoside inhibitors display pa

179 We conducted a retrospective cohort study of hepatitis C virus (HCV) patients who achieved SVR with D

180 pment of successful commercial drugs against hepatitis C virus (HCV) polymerase and HIV-1 reverse tra

181 Despite high hepatitis C virus (HCV) prevalence, opioid use disorder

182 rom high-income countries suggest increasing hepatitis C virus (HCV) prevalence/incidence among human

183 cost of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) prompted many payers to restrict

184 ersible-covalent inhibitor that binds to the hepatitis C virus (HCV) protease active site is conjugat

185 ors, and social determinants associated with hepatitis C virus (HCV) reinfection following DAA therap

186 Hepatitis B virus (HBV) and hepatitis C virus (HCV) remain, at present, the most imp

187 he development of a prophylactic vaccine for hepatitis C virus (HCV) remains a global health challeng

188 .IMPORTANCE The development of a vaccine for hepatitis C virus (HCV) remains a global health challeng

189 Hepatitis C virus (HCV) remains a significant public hea

190 Hepatitis C virus (HCV) remains endemic among people who

191 The restricted host tropism of hepatitis C virus (HCV) remains incompletely understood,

192 been reported to be necessary for efficient hepatitis C virus (HCV) replication, but the specific me

193 , it supports the establishment of efficient hepatitis C virus (HCV) replication.

194 Clearance of hepatitis C virus (HCV) results in rapid changes in meta

195 Hepatitis C virus (HCV) RNA and genotypes were determine

196 We analyzed post-treatment hepatitis C virus (HCV) RNA levels from 330 subjects who

197 Hepatitis C virus (HCV) RNA quantitation is the primary

198 We performed hepatitis C virus (HCV) RNA screening among all men who

199 S Preventive Services Task Force (USPSTF) of hepatitis C virus (HCV) screening found interferon-based

200 Hepatitis C virus (HCV) screening is critical to HCV eli

201 r demographic characteristics, behavior, and hepatitis C virus (HCV) seropositivity assessed the rela

202 This study characterizes hepatitis C virus (HCV) testing and the HCV care cascade

203 Hepatitis C virus (HCV) testing and treatment uptake in

204 Hepatitis C virus (HCV) testing in persons born from 194

205 e NS5A inhibitors underpin hugely successful hepatitis C virus (HCV) therapy.

206 Understanding hepatitis C virus (HCV) transmission among people who in

207 In the United States, hepatitis C virus (HCV) transmission is rising among peo

208 Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12

209 The revolution in hepatitis C virus (HCV) treatment through the developmen

210 fore and after widespread direct-acting anti-hepatitis C virus (HCV) treatment.

211 he effects of interferon-based therapies for hepatitis C virus (HCV) upon the risk of diabetes are co

212 The hepatitis C virus (HCV) viroporin p7 oligomerizes to for

213 Approved treatment for hepatitis C virus (HCV) with all-oral direct-acting anti

214 Treatment for hepatitis C virus (HCV) with direct-acting antivirals (D

215 Some people living with hepatitis C virus (HCV) with sustained virological respo

216 rary 2019, 532 individuals were screened for hepatitis C virus (HCV), 180 tested HCV antibody positiv

217 V.IMPORTANCE Development of vaccines against hepatitis C virus (HCV), a major cause of cirrhosis and

218 costs and disruptions in treatment for HIV, hepatitis C virus (HCV), and drug abuse.

219 ion to its known benefits on preventing HIV, hepatitis C virus (HCV), and overdose among PWID, our mo

220 an immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV), as a paradigm to model control

221 mark of a protective immune response against hepatitis C virus (HCV), associated with spontaneous vir

222 ses represent promising surrogate models for hepatitis C virus (HCV), for which there are no efficien

223 on-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV), in which an N-benzyl boronic ac

224 the existence of established treatments for hepatitis C virus (HCV), more effective means of prevent

225 Chronic hepatitis B virus (HBV), hepatitis C virus (HCV), nonalcoholic fatty liver diseas

226 Human immunodeficiency virus (HIV)-hepatitis C virus (HCV)-coinfected patients are at high

227 By deciphering mechanistic aspects of hepatitis C virus (HCV)-host interactions, one could dis

228 The mechanisms of chronic hepatitis C virus (HCV)-induced liver fibrosis and hepat

229 h men (MSMs), intravenous drug users (IDUs), hepatitis C virus (HCV)-infected and patients with diabe

230 ecies, in CD33(+) myeloid cells derived from hepatitis C virus (HCV)-infected patients.

231 milarity to eIF3 recognizing motifs found in hepatitis C virus (HCV)-like IRESs, suggesting mechanist

232 Risk factors for DGF in the hepatitis C virus (HCV)-negative recipient population in

233 irrhosis (CTP 7-9) in patients with advanced hepatitis C virus (HCV)-related cirrhosis.

234 Exhaustion of Hepatitis C Virus (HCV)-specific T cells and abnormal B

235 Outcomes following hepatitis C virus (HCV)-viremic heart transplantation in

236 Hepatitis C virus (HCV)-viremic organs are underutilized

237 he context of its activity as a receptor for hepatitis C virus (HCV).

238 r is an aryloxazole-based entry inhibitor of hepatitis C virus (HCV).

239 t recognizes the E2 envelope glycoprotein of hepatitis C virus (HCV).

240 ject drugs in the United States have chronic hepatitis C virus (HCV).

241 ika virus (ZIKV), West Nile virus (WNV), and hepatitis C virus (HCV).

242 on individuals are chronically infected with hepatitis C virus (HCV).

243 nd outcome of liver transplantation (LT) for hepatitis C virus (HCV).

244 s (NASH), alcoholic liver disease (ALC), and hepatitis C virus (HCV).

245 us (HIV; PLwH) are commonly co-infected with hepatitis C virus (HCV).

246 essential host factor for replication of the hepatitis C virus (HCV).

247 n 2 of nonstructural protein 5A (NS5A-D2) of hepatitis C virus (HCV).

248 erapy, as has recently been demonstrated for hepatitis C virus (HCV).

249 nt (DAA) that targets the NS3/4A protease of hepatitis C virus (HCV).

250 tion of retroviruses, hepatitis B virus, and hepatitis C virus (HCV).

251 e activation of CD81 [the portal of entry of hepatitis C virus (HCV)] by agonistic antibody results i

252 to develop an effective vaccine against the hepatitis C virus (HCV; human hepacivirus) have been sty

253 an T-cell lymphotropic virus types I and II, hepatitis C virus [HCV]).

254 responding to chronic viral infections (HIV, hepatitis C virus [HCV], Epstein-Barr virus [EBV], and c

255 LT registration, by disease etiology (NASH, hepatitis C virus [HCV], other liver disease etiologies

256 Hepatitis C virus' (HCV) chronic prevalence among pregna

257 , e.g., SARS-CoV-2, influenza, dengue fever, hepatitis C virus, HIV, rotavirus and Zika virus.

258 lar carcinoma (HCC) in patients with chronic hepatitis C virus; however, their impact in patients wit

259 munodeficiency virus-1/2, hepatitis B virus, hepatitis C virus, human T-cell lymphotropic virus-1/2,

260 l lines as well as antiviral effects against hepatitis C virus in the replicon assay.

261 ce of viral hepatitis (hepatitis B virus and hepatitis C virus) in migrants is higher than among the

262 viral agents, there has been a rapid rise in hepatitis C virus-infected (HCV+) heart transplantation.

263 ent hepatocellular carcinoma (HCC) in 15,059 hepatitis C virus-infected patients with advanced liver

264 njection drug use (4.89; 1.95-12.26), active hepatitis C virus infection (3.39; 1.10-12.26), and iden

265 Hepatitis C virus infection (OR, 15.84; 95% confidence i

266 ansfusions throughout her life, leading to a hepatitis C virus infection (which was treated, achievin

267 sting for race/ethnicity, age, HIV load, and hepatitis C virus infection and controlling for multipli

268 tus of direct-acting antiviral therapies for hepatitis C virus infection and discuss remaining challe

269 Screening for hepatitis C virus infection in adolescents and adults: U

270 Eliminating the burden of disease caused by hepatitis C virus infection is proving difficult, despit

271 Approximately 29.6% prevalence of Hepatitis C virus infection observed among inmates studi

272 Comparisons with hepatitis C virus infection provide insights into the re

273 Poverty, injection drug use, and hepatitis C virus infection were also associated.

274 e II diabetes (T2D) may worsen the course of hepatitis C virus infection with a greater risk of liver

275 g sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivi

276 atorvastatin or rosuvastatin or simvastatin, hepatitis C virus infection, prior treatment with busulf

277 spontaneous and IFN-alpha-dependent cure of hepatitis C virus infection.

278 eding in persons with chronic hepatitis B or hepatitis C virus infection.

279 emic has been associated with an increase in hepatitis C virus infections among women of childbearing

280 of treating human immunodeficiency virus and hepatitis C virus infections, ID physicians have unique

281 e to an effective vaccine for HCV.IMPORTANCE Hepatitis C virus infects approximately 1% of the world'

282 identification of compounds that target the hepatitis C virus internal ribosome entry site (IRES) an

283 substitutions in the NS3-4A protease of the hepatitis C virus lead to protease inhibitor (PI) resist

284 st common etiology of liver disease (LD) was hepatitis C virus (N = 48) and nonalcoholic steatohepati

285 es by diagnosis of hepatocellular carcinoma, hepatitis C virus, nonalcoholic steatohepatitis, or Medi

286 HCC) development in alcohol Western diet-fed hepatitis C virus NS5A Tg mice with hepatocyte-specific

287 even when under antiretroviral therapy), and hepatitis C virus or those of mice with lymphocytic chor

288 Hepatitis C virus-positive (HCV+) kidney transplant (KT)

289 Solid organ transplantation from hepatitis C virus-positive (HCV-positive) deceased donor

290 ration of median wait times, availability of hepatitis C virus-positive organs, and degree of liver d

291 stem is based on the interaction between the hepatitis C virus protease (HCVp) NS3a and a genetically

292 allosteric inhibitors have been reported for hepatitis C virus RdRp, few have been described for DENV

293 The hepatitis C virus RNA-dependent RNA polymerase NS5B is r

294 ound kidney disease, dialysis vintage, donor hepatitis C virus status, cardiovascular diseases, panel

295 Hepatitis C virus SVR decreased monocyte interferon gene

296 We adapted a previous model of hepatitis C virus transmission, treatment, and disease p

297 % of diagnosed cases) were initiated on anti-hepatitis C virus treatment in the Veterans Affairs heal

298 effect of sustained virological response to hepatitis C virus treatment on the progression of liver

299 2 HIV-infected patients (51% coinfected with hepatitis C virus) were included.

300 or in patients undergoing reLT for recurrent hepatitis C virus who achieved SVR after reLT compared w